FCCC LOGO Faculty Publications
Stathakis S , Roland T , Papanikolaou N , Li JS , Ma C
A Prediction Study on Radiation-induced Second Malignancies for IMRT Treatment Delivery
Technology in Cancer Research & Treatment. 2009 Apr;8(2) :141-147
PMID: ISI:000265429600007   
Back to previous list
Abstract
Low-level peripheral organ dose and its effect on second malignancies for patients undergoing radiation therapy have been reported in the literature. However, a comprehensive database outlining the treatment modalities, the tumor location, and a quantification of the overall relative risk of second malignancies is rather limited. In this work, we quantify the relative risks or percent likelihood of second malignancies for patients undergoing IMRT and conventional radiotherapy for four different tumor sites: breast, head and neck, lung, and prostate. We utilize Monte Carlo methods based on actual patient plans to compute the whole body effective dose equivalent for each plan and then deduce the percent likelihood of the occurrence of second malignancy. Based on an evaluation of over 30 actual patient plans and Monte Carlo simulations using 6, 10, and 18MV photon beam energies, we observed that the IMRT patients treated for head and neck cancer showed a 40% increase in risk for developing a second malignancy compared to those treated with conventional radiotherapy. The increase in risk for prostrate patients was 30% while the IMRT lung patients gave the highest relative risk almost tripling that observed in their conventionally treated counterparts. There was negligible difference in risk between breast patients undergoing IMRT treatment versus conventional therapy. The overall relative risk of radiation induced malignancy observed was below 6% in all treatment plans considered.
Notes
Stathakis, Sotirios Roland, Teboh Papanikolaou, Niko Li, Jinseng Ma, Charlie 31 ADENINE PRESS; 2066 CENTRAL AVE, SCHENECTADY, NY 12304 USA 436QN